The emergence of Middle East respiratory syndrome coronavirus (MERS-CoV) is of global concern -causing severe respiratory illness with 97 confirmed cases and 46 deaths 1 . Therapeutic interventions have not been evaluated in vivo, thus patient management relies exclusively on supportive care, which given the high case-fatality rate is not highly effective. The rhesus macaque is the only known disease model for MERS-CoV, developing an acute localized-towidespread pneumonia with transient clinical disease 2,3 that recapitulates mild-to-moderate human MERS-CoV cases 4,5 . The combination of interferon-Î±2b and ribavirin was effective in reducing MERS-CoV replication in vitro 6 ; therefore, this strategy was initiated 8 h post-infection in the Users may view, print, copy, download and text and data-mine the content in such documents, for the purposes of academic research, subject always to the full Conditions of use: 